Company: OCEA
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001641172-25-011080
Chunk: 110

Company: Ocean Biomedical, Inc.
Filing Date: 2025-05-15
Form: 10-Q
Item: Item 1
Chunk 110
---
 costs, accounting and legal fees, accrued research and development costs, and short-term loans.
We expect that our expense and capital requirements will increase substantially in connection with ongoing activities to commercialize
our products in the future.

36

We expect to continue to generate
operating losses for the foreseeable future. Our future viability is dependent on the success of our research and development and our
ability to access additional capital to fund our operations. There can be no assurance that our current operating plan will be achieved
or that additional funding will be available on terms acceptable to us, or at all.

We are subject to risks and uncertainties
common to early-stage companies in the biotechnology industry including, but not limited to, new technological innovations, protection
of proprietary technology, dependence on key personnel, compliance with government regulations, and the ability to obtain additional capital
to fund operations. Our therapeutic products will require significant additional research and development efforts, including preclinical
and clinical testing and regulatory approval prior to commercialization. These efforts require additional capital, adequate personnel
and extensive compliance reporting capabilities. There can be no assurance that our research and development will be successfully completed,
that adequate protection for our intellectual property will be obtained, that any products developed will obtain necessary government
regulatory approval, or that any approved products will be commercially viable.

Basis of Presentation

The Company’s condensed
consolidated financial statements were prepared in accordance with US GAAP. See Note 2, Basis of Presentation and Summary of Significant
Accounting Policies, to our condensed consolidated financial statements for a full description of our basis of presentation.

Impacts Market Conditions
on Our Business

Disruption of global financial
markets and a recession or market correction, the ongoing military conflict between Russia and Ukraine and the related sanctions imposed
against Russia, and other global macroeconomic factors such as inflation, could reduce the Company’s ability to access capital,
which could in the future negatively affect our liquidity and could materially affect our business and the value of its common stock.

Components of Our Results
of Operations

Revenue

To date, we have not generated
any revenue from any sources, including from product sales, and we do not expect to generate any revenue from the sale of products in
the foreseeable future. If our development efforts for our product candidates are successful and result in regulatory approval, or license
agreements with third parties, we may generate revenue in the future from product sales. However, there can be no assurance as to when
we will generate such revenue, if at all.